Cambridge, UK, 07 April 2020: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has contributed to two new peer-reviewed papers under the U.S. Food and Drug Administration’s (FDA) CiPA (Comprehensive in vitro Proarrhythmia Assay) initiative. The papers, in Nature Scientific Reports1 and Toxicology and Applied Pharmacology2, focus on application of improved cardiac safety testing protocols and recommendations for best practice for the drug discovery industry.
Westbury, NY – Apr. 6, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the opening of its new blood donor center on the Tufts University campus in Medford, MA to support academic and pharmaceutical researchers involved in COVID-19, cell and gene therapy research.
tranScrip (www.transcrip-partners.com) is delighted to be supporting Synairgen with their first patient dosing in a trial of SNG001 in COVID-19.
tranScrip's support in this important endeavour is a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.
Cambridge, UK - 6 April 2020 - Healx, the AI-powered, patient-inspired biotech specialising in rare diseases, today announces it is using its AI platform to develop drug combinations from approved drugs to contribute towards global efforts to find treatments for COVID-19. This focus on combination therapies, where two or more drugs simultaneously target different aspects of the disease pathology, has the potential to ensure a more effective treatment.
Cambridge, UK, 03 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.
I’ve worked from home for 9 years, starting off as Head of R&D for a virtual biotech, then as CEO of Agility Health Tech. For the last few years, I’ve hardly been at home, I was mostly on site with clients, talking at events or meeting with potential new clients. Until two weeks ago…
Following on from the success of our first webinar on EU GMP Annex 1 - Implications for Sterile Products Manufacture, RSSL are gearing up for the second installment of their three-part webinar series on manufacturing sterile pharmaceuticals.
The second webinar, to be held 6 May, will be on the topic of Reviewing Sterile Products - Examining the Factors Required for Release and will again be hosted by Dr Tim Sandle.